LDS/Medical Tests/Prostate Cancer Antigen 3 (PCA3)

Prostate Cancer Antigen 3 (PCA3)

Prostate Specific Antigen (PSA) has been used as a cancer marker for prostate for decades. However, PSA is not specific and often is increased by conditions such as benign hyperplasia of the prostate (BHP) or inflammation of the prostate (prostatitis). Prostate Cancer Antigen 3 (PCA3) is a new prostate cancer marker with significantly higher specificity for prostate cancer. PCA3 is over-expressed in over 95% of prostate cancer cases and is not affected by BHP or inflammatory prostate conditions.

Therefore, PCA3 is a new prostate tumor marker used to improve prostate cancer detection and diagnosis. It is also used to identify the asymptomatic and more aggressive forms of prostate cancer, and to reduce the number of biopsies and lower the risk of pain, bleeding and infection inpatients.

The PCA3 gene is located on chromosome 9 and is transcribed into a non-coding prostate-specific mRNA which is overexpressed in tumor cells by a factor of 60 to 100 compared to normal prostate tissue. PCA3 is not a “screening” test for cancer. The test is used for diagnosis and management of prostate cancer in conjunction with serum levels of PSA, digital rectal examination and any previous history of prostate cancer. The test uses the PCA3 score which is determined based on the ratio of PCA3/PSA RNA. In addition to normalizing the PCA3 signal, measurement of PSA RNA also serves to confirm that the yield of prostate-specific RNA is sufficient to generate a valid result. Higher PCA3 Scores correlate with higher probability of a positive prostate biopsy.

  • As an aid in diagnosis of prostate cancer
  • Prostate cancer management and therapy monitoring
  • Negative: PCA3 ratio 0-17 (if the cutoff is 25)
  • Decreased likelihood of a positive biopsy: PCA3 ratio 18-24 (Ratios in the range of 18-24 should be interpreted with caution)
  • Increased likelihood of a positive biopsy: PCA3 ratio 25-31 (The ratio in the range of 25-31 should be interpreted with caution)
  • Positive: PCA3 ratio >31. Most likely associated with increased probability of a positive biopsy for prostate cancer

Note: PCA3 ratios may vary upon repeat testing.

 

<25 PCA3 Score

Transcription mediated amplification is normalized to the amount of PSA mRNA evaluated in the same urine sample in order to calculate the PCA3 score: PCA3 mRNA/PSA mRNA x 1000.

The test is conducted on a urine sample, 20-30 ml, after digital-rectal examination. The sample is collected in a sterile urine container. Specimen can be transferred to a transport media after the collection or upon arrival in the lab.

Stability

Urine collected in sterile container

  • Refrigerated: up to five days
  • Frozen: 14 days or longer
Prostate-Specific Antigen (PSA) total and free, prostate biopsy.

3-5 days.

Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login